Category: InSightec LtdSyndicate content

InSightec seeks $50M for ultrasound tumor therapy

June 30, 2014 by Arezu Sarvestani

InSightec launches a $50 million Series D funding round in support of its MR-guided ultrasound treatment, hoping to boost the round to $62.5 million.

InSightec seeks $50M for ultrasound tumor therapy

Israel-based InSightec is looking for a few investors to jump in on its $50 million Series D funding round, saying it'll use the funds to boost commercial efforts for its non-invasive tumor-targeting ultrasound therapy.

York Capital Management is already lined up to take a chunk out of the $50 million, leaving "limited time" for other prospective funders to jump in on the initial round or to expand fundraising to $62.5 million, InSightec said.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Canada green-lights InSightec's ablation system

August 22, 2013 by Sony Salzman

Canadian regulators give InSightec a nod of approval for the ExAblate system to treat benign uterine tumors and painful metastatic bone tumors.

Canada green-lights InSightec's ablation system

Canadian healthcare regulators approved InSightec's ExAblate ultrasound system, clearing the device for use against 2 different diseases. Health Canada granted ExAblate indication to break up benign uterine tumors and to alleviate painful symptoms of metastatic bone tumors.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Insightec lands Chinese approval for ExAblate ultrasound tumor ablation

July 31, 2013 by Sony Salzman

Chinese regulators hand InSightec regulatory approval for the ExAblate ultrasound-based therapy to treat non-cancerous uterine tumors.

Insightec's ExAblate system

Israeli device maker InSightec landed a green light from the Chinese Food & Drug Administration for its ExAblate MRI-guided focused ultrasound therapy, with an indication to treat non-cancer-causing tumors in the uterus.

These tumors, called uterine fibroids, occur in more than 20% of women of childbearing age, according to the company. ExAblate is an incision-free treatment that uses ultrasound frequencies to ablate tumors.

Funding: InSightec closes $30.9 million Series C round

December 10, 2012 by MassDevice staff

InSightec completes $30.9 million Series C financing round, led by GE Healthcare and other investors. Lands CE Marked approval for its ExAblate Neuro in the treatment of Parkinson's disease.

InSightec picked off $30.9 million in a Series C financing round, led by a $27.6 million investment from GE Healthcare and $3.3 million by other investors, the company said.

In addition, the Israeli-based ultrasound maker also named VP & general manager of the MRI business James Davis as new CEO and Tom Gentile as chairman of board. Gentile most recently was
president & CEO of GE Healthcare.

FDA approves InSightec's ultrasound-based ExAblate pain treatment system

October 23, 2012 by MassDevice staff

Israeli device maker InSightec lands FDA approval to treat painful bone metastases with its ExAblate ultrasound-based therapy.

Insightec's ExAblate system

Israeli device maker InSightec won FDA approval for its ExAblate MRI-guided focused ultrasound therapy with indication to treat pain resulting from bone metastases in patients who failed or aren't good candidates for radiation therapy.

Bone metastases occur when cancer cells break off from the primary tumor site and spread to other parts of the body, commonly leaving patients with significant physical and emotional pain, according to a press release.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

FDA approves brain ultrasound study with InSightec's ExAblate Neuro

August 20, 2012 by MassDevice staff

The FDA approves clinical trials of InSightec's ExAblate Neuro in treatment of medication-resistant Parkinson's disease.

Insightec's ExAblate Neuro

The FDA approved U.S. studies of Israel-based InSightec's ExAblate Neuro in treatment of medication resistant Parkinson's disease.

InSightec will enroll 30 patients who suffer from tremors associated with the disease, randomizing them for treatment with ultrasound-based deep-lesioning of the brain.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp